{"contentid": 488074, "importid": NaN, "name": "Sobi's novel peptide beats competition in rare disease", "introduction": "Results from the Phase III PEGASUS trial have been published by Nordic rare diseases firm Swedish Orphan Biovitrum, also known as Sobi, and its partner Apellis Pharmaceuticals.", "content": "<p>Results from the Phase III PEGASUS trial have been published by Nordic rare diseases firm Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, and its partner Apellis Pharmaceuticals (Nasdaq: APLS).</p>\n<p>The firms are developing a synthetic peptide, pegcetacoplan, which regulates a key part of the body's immune system.</p>\n<p>Top-line data for the targeted C3 therapy, announced in December 2020, showed it led to sustained hematological and clinical improvements for people with paroxysmal nocturnal hemoglobinuria (PNH).</p>\n<p>The trial showed Sobi and Apellis&rsquo; option was superior in reducing hemoglobin levels compared with eculizumab, which is marketed by Alexion Pharmaceuticals&rsquo; (Nasdaq: ALXN) as Soliris.</p>\n<p>In addition, 85% of pegcetacoplan-treated patients were transfusion free over 16 weeks versus 15% of eculizumab-treated patients.</p>\n<p>The results could be significant, given that Alexion&rsquo;s blockbuster therapy generated over $4 billion in revenues last year.</p>\n<p>Spying an opportunity across treatment settings, the firms plan to jointly advance five parallel registration programs including two new registrational programs in hematology this year.</p>\n<p>As well as in PNH, Sobi and Apellis plan to test pegcetacoplan as an option for cold agglutinin disease (CAD) and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), plus indications in nephrology and neurology.</p>\n<h2>Collaboration</h2>\n<p>Since late 2020, Sobi has been working with Apellis, a USA-based firm, under the terms of a co-development and commercialization deal for pegcetacoplan.</p>\n<p>As well as working together on global development of the therapy, Sobi gained exclusive ex-US commercialization rights in return for $250 million upfront and up to around a billion dollars in milestones, plus royalties on sales.</p>\n<p>Reacting to the publication, Apellis chief medical officer Federico Grossi said that, &ldquo;if approved, pegcetacoplan has the potential to elevate the standard of care for PNH by providing more complete disease control.\"</p>\n<p>He added: \"We are working to quickly bring this potential new treatment to PNH patients and to advance development of pegcetacoplan for many other serious, complement-driven diseases.\"</p>\n<p>Marketing applications for pegcetacoplan for the treatment of PNH are under review in the USA and in Europe. A decision is expected from the US Food and Drug Administration by May 14, 2021.</p>", "date": "2021-03-18 10:24:00", "meta_title": NaN, "meta_keywords": "Sobi, Apellis, rare, pegcetacoplan, Pharmaceuticals, trial, results, disease, firm, diseases, peptide, competition, beats, Nordic, PEGASUS, Phase, publishe", "meta_description": "Results from the Phase III PEGASUS trial have been published by Nordic rare diseases firm Swedish Orphan Biovitrum, also known as Sobi, and its partner Apellis ", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-18 10:06:22", "updated": "2021-03-18 10:28:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/sobi-s-novel-peptide-beats-competition-in-rare-disease", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vials_research_lab_biotech_big.jpg", "image2id": "vials_research_lab_biotech_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Rare diseases", "topic_tag": "Drug Trial, Research", "geography_tag": "Sweden, USA", "company_tag": "Alexion Pharmaceuticals, Apellis Pharmaceuticals, Swedish Orphan Biovitrum", "drug_tag": "pegcetacoplan, Soliris", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-18 10:24:00"}